Anondita Medicare Limited Secures Purchase Order from Central Medical Services Society for Condoms
Anondita Medicare Limited has received a significant purchase order for the supply of condoms from the Central Medical Services Society (CMSS), which operates under the Ministry of Health and Family Welfare, Government of India.The purchase order, identified as PO No: 10282600131/PDI/Domestic Fund-DF, was issued on April 28, 2026. The order pertains to the supply of Condoms (FSNACO) [379].
The total value of the contract awarded to Anondita Medicare Limited is Rs. 7,18,36,178.310/- (Rupees Seven Crore Eighteen Lakhs Thirty-Six Thousand One Hundred Seventy-Eight and Thirty- One Paisa Only).
According to the details provided, the order has specific terms and conditions governing its execution. Regarding payment and security, the contract mandates the deposit of Performance Security @3% of the total value. Payment terms are set at within 75 days of supplies for items requiring sterility tests, and within 60 days for other items.
The supply is structured in two tranches. Tranche I (PDI) requires 50% delivery within 90 days from the date of the purchase order issue. Tranche II (PDI) involves the delivery of the remaining 50% balance within 91 to 180 days from the purchase order date.
Key details of the contract awarded to Anondita Medicare Limited are summarized below:
| Detail Category | Description |
|---|---|
| Awarding Entity | Central Medical Services Society, Ministry of Health and Family Welfare (Government of India) |
| Nature of Order | Supply of Condoms (FSNACO) [379] |
| Contract Value | Rs. 7,18,36,178.310/- |
| Performance Security | 3% of the total value |
| Payment Terms | Within 75 days (sterility test items); Within 60 days (other items) |
| Delivery Timeline | Tranche I (50%): Within 90 days; Tranche II (50%): Within 91-180 days |
ANONDITA Stock Price Movement
Shares of Anondita Medicare Limited are rallying to ₹1067.95 as of 9:55 AM today, gaining 2.43% in live trading. The stock has seen 400 shares transacted so far, bolstering its momentum in the market.Disclaimer: Due care and diligence have been taken in compiling and presenting news and market-related content. However, errors or omissions may arise despite such efforts.
The information provided is for general informational purposes only and does not constitute investment advice, a recommendation, or an offer to buy or sell any securities. Readers are advised to rely on their own assessment and judgment and consult appropriate financial advisers, if required, before taking any investment-related decisions.
Any views, opinions, or statements expressed, where applicable, are those of the respective analysts or experts and do not reflect the views of this website. The website has no association with such viewpoints and does not assume any responsibility for them.